Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.

BACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI) nephrotoxicity....

Description complète

Détails bibliographiques
Auteurs principaux:	Haynes, R, Baigent, C, Harden, P, Landray, M, Akyol, M, Asderakis, A, Baxter, A, Bhandari, S, Chowdhury, P, Clancy, M, Emberson, J, Gibbs, P, Hammad, A, Herrington, W, Jayne, K, Jones, G, Krishnan, N, Lay, M, Lewis, D, Macdougall, I, Nathan, C, Neuberger, J, Newstead, C, Pararajasingam, R, Puliatti, C
Format:	Journal article
Langue:	English
Publié:	2013

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.

Documents similaires